Roginolisib is in development for solid and hematologic malignancies including uveal melanoma GENEVA and AMSTERDAM, Oct. 31, 2023 /PRNewswire/ — iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.